• Record Underlying EBITDA of $5.1M, up $8.5M over FY24
• FY25 revenue of $40.8M, up 10% on prior year
• Annual Recurring Revenue (ARR) of $28.5M, up 31% on prior year

Alcidion Group Limited (ASX:ALC) has released its audited Financial Statements and Annual Report for the Financial Year ended 30 June 2025 (FY25). The company reported record Underlying EBITDA of $5.1M, an $8.5M improvement over FY24, and $5.8M in positive operating cashflow. FY25 revenue was $40.8M, up 10% on the prior corresponding period, with a geographical split of 63% UK and 37% ANZ. Annual Recurring Revenue (ARR) as at 30 June 2025 was $28.5M, up 31% on the prior year. The company signed several major new customer contracts during the year, including a $39M+ 10-year EPR contract with North Cumbria NHS Trust in the UK, as well as new partnerships in Australia with Hume Rural Health Alliance, Northern Adelaide Local Health Network, and Peninsula Health. Alcidion also expanded and extended multiple existing customer contracts. The company strengthened its leadership team with the appointment of a new Managing Director UK, UK Chief Revenue Officer, and Chief Clinical Information Officer. As of 30 June 2025, Alcidion has $34M of contracted and renewal revenue able to be recognised in FY26, which the company expects to further build upon during the year as new sales are won. The company expects to be EBITDA and operating cashflow positive in FY26, with the quantum subject to the timing and size of new contract wins.

Alcidion expects to be EBITDA and operating cashflow positive in FY26, with the quantum subject to the timing and size of new contract wins.

Alcidion has approximately $140M of contracted revenue to be recognised out to 2030 as a result of the material new TCV added in FY25. The company expects to continue growing its contracted revenue during FY26 as new contracts are signed, as demonstrated in FY25. Alcidion will provide a further update on its growth strategy as part of a roadshow presentation in mid-September 2025.